Effect of long non-coding RNA SLCO4A1-AS1 targeting microRNA-615-5p on the proliferation, apoptosis and inflammatory factors expression in esophageal cancer cells

Kabinuer·ALIMASI; CHEN Hailin; Aishanjiang·MUHETAER; Maimaitirexiati·SUPAJI; WU Chunping; Anniwaer·MAIMAITI

doi:10.7619/jcmp.20233173

Journal of Clinical Medicine in Practice > 2024 > 28(1): 13-19. > DOI: 10.7619/jcmp.20233173

Kabinuer·ALIMASI, CHEN Hailin, Aishanjiang·MUHETAER, Maimaitirexiati·SUPAJI, WU Chunping, Anniwaer·MAIMAITI. Effect of long non-coding RNA SLCO4A1-AS1 targeting microRNA-615-5p on the proliferation, apoptosis and inflammatory factors expression in esophageal cancer cells[J]. Journal of Clinical Medicine in Practice, 2024, 28(1): 13-19. DOI: 10.7619/jcmp.20233173

Citation:

PDF (2688 KB)

Effect of long non-coding RNA SLCO4A1-AS1 targeting microRNA-615-5p on the proliferation, apoptosis and inflammatory factors expression in esophageal cancer cells

Department of Thoracic Surgery, the First People's Hospital of Kashi Region in Xinjiang, Kashi Hospital Affiliated to Sun Yat-sen University, Kashi, Xinjiang, 844000

More Information

Received Date: October 08, 2023
Revised Date: December 05, 2023
Available Online: January 22, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the effects of long non-coding RNA (LncRNA) solute carrier organic anion transporter family member 4A1 (SLCO4A1-AS1) targeting microRNA-615-5p (miR-615-5p) in esophageal cancer cells on cell proliferation, apoptosis, and expression of inflammatory factors.
Methods
Real-time quantitative polymerase chain reaction (RT-qPCR) was used to analyze the expression of LncRNA SLCO4A1-AS1 and miR-615-5p in esophageal cancer tissues and cell lines. Eca109 cells were transfected with si-NC, si-LncRNA SLCO4A1-AS1, miR-NC, miR-615-5p mimic, pcDNA, pcDNA-LncRNA SLCO4A1-AS1, si-LncRNA SLCO4A1-AS1+anti-miR-NC, and si-LncRNA SLCO4A1-AS1+anti-miR-615-5p. Cell viability and apoptosis rate were measured by CCK-8 and flow cytometry, respectively; cell proliferation was determined by plate cloning assay; and levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) in the culture medium were measured using an enzyme-linked immunosorbent assay (ELISA) kit. A dual luciferase reporter gene assay was used to determine the relationship between LncRNA SLCO4A1-AS1 and miR-615-5p.
Results
Expression of LncRNA SLCO4A1-AS1 was upregulated, and miR-615-5p expression was downregulated in esophageal cancer tissues and cell lines. After inhibiting LncRNA SLCO4A1-AS1 expression, cell viability, the number of cell clones, and levels of IL-6 and TNF-α in the culture medium decreased, while miR-615-5p expression and apoptosis rate increased (P < 0.05). Compared with the miR-NC group, the miR-615-5p group showed increased miR-615-5p expression, levels of Cleaved-caspase-3 protein, and apoptosis rate, and decreased cell viability, the number of cell clones, and levels of IL-6 and TNF-α in the culture medium (P < 0.05). Compared with the si-LncRNA SLCO4A1-AS1+anti-miR-NC group, the si-LncRNA SLCO4A1-AS1+anti-miR-615-5p group showed decreased miR-615-5p expression, levels of Cleaved-caspase-3 protein, and apoptosis rate, and increased cell viability, the number of cell clones, and levels of IL-6 and TNF-α in the culture medium (P < 0.05).
Conclusion
LncRNA SLCO4A1-AS1 can promote the occurrence and development of esophageal cancer. Inhibiting LncRNA SLCO4A1-AS1 can reduce the proliferation of esophageal cancer cells, decrease the expression of inflammatory factors, and induce apoptosis.
- esophageal cancer,
- long non-coding RNA SLCO4A1-AS1,
- microRNA-615-5p,
- proliferation,
- inflammation,
- apoptosis

FullText(HTML)

References (22)

References

[1]	刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.
[2]	UHLENHOPP D J, THEN E O, SUNKARA T, et al. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors[J]. Clin J Gastroenterol, 2020, 13(6): 1010-1021. doi: 10.1007/s12328-020-01237-x
[3]	CODIPILLY D C, QIN Y, DAWSEY S M, et al. Screening for esophageal squamous cell carcinoma: recent advances[J]. Gastrointest Endosc, 2018, 88(3): 413-426. doi: 10.1016/j.gie.2018.04.2352
[4]	沈钲杰, 朱银银, 沈凡含, 等. lncRNA与miRNA调节关系和ceRNA关系在疾病中的研究进展[J]. 中国细胞生物学学报, 2018, 40(10): 1774-1780.
[5]	赵志国, 张力平. miRNA和lncRNA相互作用与恶性肿瘤相关性的研究进展[J]. 现代肿瘤医学, 2018, 26(18): 2991-2994. doi: 10.3969/j.issn.1672-4992.2018.18.040
[6]	YU J T, HAN Z Y, SUN Z Q, et al. LncRNA SLCO4A1-AS1 facilitates growth and metastasis of colorectal cancer through β-catenin-dependent Wnt pathway[J]. J Exp Clin Cancer Res, 2018, 37(1): 222. doi: 10.1186/s13046-018-0896-y
[7]	YANG Y, WANG F, HUANG H, et al. lncRNA SLCO4A1-AS1 promotes growth and invasion of bladder cancer through sponging miR-335-5p to upregulate OCT4[J]. Onco Targets Ther, 2019, 12: 1351-1358. doi: 10.2147/OTT.S191740
[8]	YANG B Y, XIE R, WU S N, et al. MicroRNA-615-5p targets insulin-like growth factor 2 and exerts tumor-suppressing functions in human esophageal squamous cell carcinoma[J]. Oncol Rep, 2018, 39(1): 255-263.
[9]	LI Q P, JIANG B, QI Y, et al. Long non-coding RNA SLCO4A1-AS1 drives the progression of non-small-cell lung cancer by modulating miR-223-3p/IKKα/NF-κB signaling[J]. Cancer Biol Ther, 2020, 21(9): 806-814. doi: 10.1080/15384047.2020.1787757
[10]	WU K, XU T, SONG X D, et al. LncRNA SLCO4A1-AS1 modulates colon cancer stem cell properties by binding to miR-150-3p and positively regulating SLCO4A1[J]. Lab Invest, 2021, 101(7): 908-920. doi: 10.1038/s41374-021-00577-7
[11]	WEI Y X, WEI L, LI J W, et al. SLCO4A1-AS1 promotes cell growth and induces resistance in lung adenocarcinoma by modulating miR-4701-5p/NFE2L1 axis to activate WNT pathway[J]. Cancer Med, 2020, 9(19): 7205-7217. doi: 10.1002/cam4.3270
[12]	MAO J P, GAO W L, XUE L G, et al. The lncRNA SLCO4A1-AS1/miR-876-3p/RBBP6 axis regulates cell proliferation and apoptosis in acute lymphocytic leukemia via the JNK signaling pathway[J]. Int J Lab Hematol, 2021, 43(5): 1050-1061. doi: 10.1111/ijlh.13501
[13]	TANG R, CHEN J H, TANG M T, et al. LncRNA SLCO4A1-AS1 predicts poor prognosis and promotes proliferation and metastasis via the EGFR/MAPK pathway in colorectal cancer[J]. Int J Biol Sci, 2019, 15(13): 2885-2896. doi: 10.7150/ijbs.38041
[14]	LIN E W, KARAKASHEVA T A, HICKS P D, et al. The tumor microenvironment in esophageal cancer[J]. Oncogene, 2016, 35(41): 5337-5349. doi: 10.1038/onc.2016.34
[15]	刘良忠, 李小红, 马楼艳, 等. 白细胞介素37对食管癌细胞增殖、迁移、炎症反应的影响及其机制[J]. 山东医药, 2016, 56(45): 34-37. doi: 10.3969/j.issn.1002-266X.2016.45.010
[16]	FANG Y T, SUN B, GAO J P, et al. LncRNA SLCO4A1-AS1 accelerates growth and metastasis of gastric cancer via regulation of the miR-149/XIAP axis[J]. Front Oncol, 2021, 11: 683256. doi: 10.3389/fonc.2021.683256
[17]	WANG Z Z, JIN J J. LncRNA SLCO4A1-AS1 promotes colorectal cancer cell proliferation by enhancing autophagy via miR-508-3p/PARD3 axis[J]. Aging, 2019, 11(14): 4876-4889. doi: 10.18632/aging.102081
[18]	ZHANG M Q, LIN B Q, LIU Y M, et al. LINC00324 affects non-small cell lung cancer cell proliferation and invasion through regulation of the miR-139-5p/IGF1R axis[J]. Mol Cell Biochem, 2020, 473(1/2): 193-202.
[19]	GAO W, GU Y, LI Z, et al. MiR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma[J]. Oncogene, 2015, 34(13): 1629-1640. doi: 10.1038/onc.2014.101
[20]	GUAN X, ZONG Z H, LIU Y, et al. circPUM1 promotes tumorigenesis and progression of ovarian cancer by sponging miR-615-5p and miR-6753-5p[J]. Mol Ther Nucleic Acids, 2019, 18: 882-892. doi: 10.1016/j.omtn.2019.09.032
[21]	陈刚, 王国栋, 王乃辉. mir-615-5p通过靶向调节癌基因TRAF4抑制非小细胞肺癌细胞的增殖[J]. 中国生物化学与分子生物学报, 2016, 32(2): 184-190.
[22]	LIANG Z Y, ZHAO B S, HOU J S, et al. CircRNA circ-OGDH (hsa_circ_0003340) acts as a ceRNA to regulate glutamine metabolism and esophageal squamous cell carcinoma progression by the miR-615-5p/PDX1 axis[J]. Cancer Manag Res, 2021, 13: 3041-3053. doi: 10.2147/CMAR.S290088

[1]	WANG Yulin, YANG Dandan, LI Wenwen, LYU Xiaojun, ZHANG Xiaoqian. Bibliometrics-based analysis of research hotspots and trends in microbial-gut-brain axis[J]. Journal of Clinical Medicine in Practice, 2025, 29(7): 43-49. DOI: 10.7619/jcmp.20245847
[2]	ZHU Yongmei, DU Lin, WANG Dan. Relationships of urinary liver-type fatty acid-binding protein and serum galectin-3 with early renal dysfunction in gout patients[J]. Journal of Clinical Medicine in Practice, 2024, 28(18): 76-80. DOI: 10.7619/jcmp.20241618
[3]	XU Manling, ZHU Jingbo, YU Kaiwen, CHEN Ling, FAN Huaying, FAN Qingtao, WANG Qiuping, LU Yan. Correlations of serum Apelin-13 and fatty acid binding protein 4 levels with postmenopausal osteoporosis[J]. Journal of Clinical Medicine in Practice, 2024, 28(11): 73-78, 83. DOI: 10.7619/jcmp.20240004
[4]	LIN Li, GU Cuihong, WANG Shuo, HUANG Shuyi, WANG Lihong, ZHANG Zhihua. Roles of short-chain fatty acid in antibiotic-associated diarrhea and its mechanism[J]. Journal of Clinical Medicine in Practice, 2023, 27(19): 61-66. DOI: 10.7619/jcmp.20232145
[5]	DAI Min, YANG Zichang, HU Ruilin, LI Qianqian, YI Jianmin, YU Qi. Values of brain fatty-type acid binding protein and kallikrein-6 in peripheral blood in predicting postoperative cognitive dysfunction of senile patients with hip replacement[J]. Journal of Clinical Medicine in Practice, 2023, 27(12): 44-49. DOI: 10.7619/jcmp.20230999
[6]	SHAO Huijuan, ZHENG Xiaofeng, HUANG Jun, MA Xuefeng, YU Xiaohui, ZHANG Jiucong. Research progress on roles of bile acids and its receptors in pathogenesis of non-alcoholic fatty liver disease and pharmacological treatment[J]. Journal of Clinical Medicine in Practice, 2023, 27(9): 143-148. DOI: 10.7619/jcmp.20230573
[7]	GAO Jie, YI Wei, LYU Shanshan, ZHANG Ting, ZHAO Rong. Diagnostic value of combined detection of serum heart-typefatty acid binding protein as well as non-esterified fatty acid for postoperative myocardial injury after percutaneous coronary intervention in elderly patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2021, 25(21): 28-32. DOI: 10.7619/jcmp.20212194
[8]	YU Miao, ZHANG Li, QIN Bing, HU Daojun. Relationship between serum free fatty acids level and insulin resistance in patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2018, (7): 120-122. DOI: 10.7619/jcmp.201807034
[9]	ZHU Rongfeng, CHEN Suhong, GU Bin, HUANG Shengli. Relevance exploration of blood free fatty acid, uric acid and Testosterone with C peptide in male patients with incipient type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2014, (15): 8-10. DOI: 10.7619/jcmp.201415003
[10]	DING Ya-ping, XU Qin, WANG Jian-hua, SHEN Li-zong, ZHAO Yi, WANG Ling, WU Wen-xi. THE EFFECT OF TOTAL PARENTERAL NUTRITION SUPPLEMENTED WITH SHORT-CHAIN FATTYACIDS OF THE PROLIFERATION OF COLON MUCOSAL CELLS IN RATS WITH POSTOPERATIVE CHEMOTHERAPY[J]. Journal of Clinical Medicine in Practice, 2006, (9): 38-41. DOI: 10.3969/j.issn.1672-2353.2006.09.012

Cited By

Cited by

Periodical cited type(4)

1.	殷浩，余利军，方婷婷. 舒筋壮骨汤结合经皮椎体成形术治疗骨质疏松压缩性脊柱骨折对患者腰椎功能和骨代谢水平的影响. 中国中西医结合外科杂志. 2023(01): 47-51 .
2.	毕雪洁，周刘德. 椎体成形术与椎体后凸成形术对骨质疏松性椎体压缩性骨折患者骨代谢及腰椎功能的影响比较. 黑龙江医学. 2022(13): 1557-1559 .
3.	黄松，陈敬有，魏优秀，周伟. 矿化胶原改性骨水泥在骨质疏松性椎体压缩骨折经皮椎体成形术中的临床应用. 创伤外科杂志. 2021(05): 350-354 .
4.	王强，张骏，王天，刘万舜，谭章勇. 经皮椎体成形术治疗骨质疏松性椎体压缩骨折的临床疗效及术后邻近椎体骨折的危险因素分析. 现代生物医学进展. 2021(21): 4095-4099 .

Other cited types(0)

Get Citation

PDF

XML

Article views (124) PDF downloads (9) Cited by(4)

Turn off MathJax

Article Contents

Abstract

References

Effect of long non-coding RNA SLCO4A1-AS1 targeting microRNA-615-5p on the proliferation, apoptosis and inflammatory factors expression in esophageal cancer cells